Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
RESEARCH TOOLSreports
Neurosense Therapeutics Ltd. (NRSN) Stock Price & Analysis
86 Followers
NRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.40 - $2.33
Previous Close$1.23
Volume350.96K
Average Volume (3M)186.07K
Market Cap
$22.19M
Enterprise Value$18.75M
Total Cash (Recent Filing)$3.58M
Total Debt (Recent Filing)$147.00K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 28, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding15,379,042
10 Day Avg. Volume98,093
30 Day Avg. Volume186,073
Standard Deviation0.52
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)2.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit243.50
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$3.00Price Target Upside143.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Neurosense Therapeutics Ltd. News
PremiumCompany Announcements
NeuroSense Shareholders Approve Key Resolutions
PremiumCompany Announcements
NeuroSense’s PrimeC Shows Promise in ALS Study
PremiumCompany Announcements
NeuroSense Extends Warrant Termination, Revises Terms
PremiumCompany Announcements
NeuroSense Advances ALS Treatment, Eyes Phase 3 Trial
PremiumCompany Announcements
NeuroSense Challenges Nasdaq Delisting NoticeBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPrimeC has demonstrated a significant slowdown in disease progression for ALS patients, improving survival rates and functional abilities.
Patient Enrollment And Study ContinuationA high percentage of patients continued into the open-label extension, indicating strong confidence in PrimeC's benefits.
Treatment EfficacyPrimeC has shown a 40% slowdown in disease progression, offering promising potential in treating ALS effectively.
Bears Say
Capital NeedsA capital raise will be required to continue operations, which is impacting the stock price.
Financial PerformanceThe financing overhang is affecting the stock price along with the perception of the small sample size.
Stock PerformanceThe stock traded down 24%, likely because the secondary endpoints did not reach statistical significance.
---
Ownership Overview
0.00%
Insiders
0.07% Mutual Funds
0.39% Other Institutional Investors
99.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.40 and its highest was $2.33 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Aug 28, 2024 which is in 52 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Currently, no data Available
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -$0.19.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 18,037,006 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Among the largest hedge funds holding Neurosense Therapeutics Ltd.’s share is Woodline Partners LP. It holds Neurosense Therapeutics Ltd.’s shares valued at 36K.
---
Neurosense Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (143.90% Upside)
$3.00 (143.90% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.7%
Last 30 Days ▲ 18.6%
Last 30 Days ▲ 18.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-72.90%
Trailing 12-Months
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
---
NRSN Stock 12 Month Forecast
Average Price Target
$3.00
▲(143.90% Upside)
Technical Analysis
Best Analysts Covering NRSN
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
-12.50%
reiterated a buy rating 5 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -12.50% per trade.
---